The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Anticancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and a platinum agent.
 
Sarah Patricia Blagden
Stock and Other Ownership Interests - RNA Guardian; RNA Guardian (I)
Speakers' Bureau - Clovis Oncology; OCTIMET
Research Funding - Incyte (Inst); Nucana (Inst); octimet (Inst); Piqur (Inst); Redx Pharma (Inst); Sierra Pharma (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - WO 2016075455 A1 circulating LARP1
Travel, Accommodations, Expenses - Nucana; Tesaro
 
Jennifer Bré
Research Funding - Nucana (Inst)
Travel, Accommodations, Expenses - Nucana
 
Peter Mullen
Research Funding - Nucana (Inst)
 
Chathunissa Gnanaranjan
No Relationships to Disclose
 
Essam Ahmed Ghazaly
No Relationships to Disclose
 
Mairead Geraldine McNamara
Consulting or Advisory Role - Ipsen; Shire; Sirtex Medical
Speakers' Bureau - Nucana
Research Funding - Ipsen; Nucana; SERVIER
Travel, Accommodations, Expenses - Bayer
 
Juan W. Valle
Honoraria - Ipsen
Consulting or Advisory Role - Agios; AstraZeneca; Delcath Systems; Genoscience Pharma; Incyte; Ipsen; Keocyt; Merck; Mundipharma; Novartis; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics
Speakers' Bureau - Imaging Equipment Limited; Ipsen; Novartis; Nucana
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - Celgene; Nucana